While Bicycle clings to the hope of first-line treatment, Innate eyes a post-Padcev fast track.

JBZ-001, acquired last year, features with CD-001 and ADCE-D01 among recent clinical trial entrants.

Felmetatug vedotin’s exit could be bad news for Mersana.

The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.

Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.

AstraZeneca bags three of the month’s four oncology approvals.